WO2007113646B1 - A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof - Google Patents
A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereofInfo
- Publication number
- WO2007113646B1 WO2007113646B1 PCT/IB2007/000856 IB2007000856W WO2007113646B1 WO 2007113646 B1 WO2007113646 B1 WO 2007113646B1 IB 2007000856 W IB2007000856 W IB 2007000856W WO 2007113646 B1 WO2007113646 B1 WO 2007113646B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorophytum
- polysaccharide
- polysaccharides
- water
- plant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The present invention is directed towards immunity enhancing activity in Chlorophytum (Safed Musli) due to a novel gel ' forming aqueous extract of Chlorophytum (Safed Musli) or its partially or completely purified carbohydrate (polysaccharide), and thereby Chlorophytum or its aqueous extract or gel or carbohydrates form useful and safe health promoting substances that can be consumed alone or as additive in food, food products etc. or as functional food, dietary substances and nutraceutical. Further, the bioactive substance compositions comprising novel carbohydrates particularly but not limited to Chlorophytum or Musli glucomannan (MGM) discovered herein from the plant. Thus the plant, plant aqueous extract, partially purified or completely purified carbohydrate products and its associated processes, properties, uses and applications in any mode form the components of this invention. The novel bioactive polysaccharide/ heteroglycan of the plant invented herein preparations are positive biomodulators for mammalian physiology to jack-up its immune defence in normal as well as diseased and ailing individuals. These compositions if consumed orally or otherwise would improve the well being of mammals suffering from or susceptible to a variety of bodily inefficient functions or disorders in general and immune system related ones in particular. The invention allows alternate designation of Chlorophytum as Indian Konjac.
Claims
1. Use of tubers/ fingers (fasciculated roots) of Chlorophytum Sp. (Safed musli) either individually or in combination as an immunomodulating agent comprising upto 45% (w/w) isolated polysaccharides, 7 to 10 % (w/w) proteins and 40 to 50% (w/w) of other constituents such as fiber, cellulose, pectin, hemicellulose and free sugars.
2. The use as claimed in claim 1, wherein the plant used is Chlorophytum borivilliaπum.
3. The use as claimed in claim 1, wherein the isolated polysaccharide is a herteroglycan comprising of a polymer of glucose and mannose as constituent units with a molecular weight of more than 200 KDa.
4. The use as claimed in claim 11 wherein the isolated polysaccharide fraction is water extractable easily water soluble polysaccharides,
5. The use as claimed in claim 1 , wherein the isolated polysaccharide fraction is water extractable hydro-suspension polysaccharides.
6. A pharmaceutical composition useful as an immunomodulating agent comprising isolated polysaccharide fractions from the plant Chlorophytum borivilliaπum consisting of water extractable easily water soluble polysaccharides and water extractable hydro-suspension polysaccharides either alone or in combination optionally along with pharmaceutically acceptable excipients.
7. A composition as claimed in claim 6, wherein the fraction is isolated from Chlorophytum borivillianum,
8. A composition as claimed in- claim 6, wherein the plant ttssue/biomass used is preferably aerial or tubers/ fingers (fasciculated roots) or mixtures thereof.
9. A composition as claimed in claim 6, wherein the plant tissue/biomass is extracted or used fresh or dry and may be native or peeled or in any other physical form.
10. A composition as claimed in claim 6, wherein the dose is 50 to iQ0mg/Kg body weight administered orally for a period of 1-28days.
25
11. A composition as claimed in claim 6, wherein the amount of RBCs used to induce the humorral immunity was 0.2 mi of 1 x 108 red blood cells
12. A composition as claimed in claim 6, being non toxic in rodents as experimentally studied upto a dose of 2000mg/Kg body weight in single oral dose.
13. A composition as claimed in claim 6, wherein its humoral immunomodulatory activity is greater than levamisole,
14. A composition as claimed in claim 6, wherein the cell mediated immunomodulatory activity is greater than normal and cyclophosphamide treated animals,
15. A process for the isolation of bioactive polysaccharides from Chlaraphytum sp (Safed musli) comprising the steps of :
[a] homogenizing or otherwise solvation of the Chlorophytum borivillianum tissue or biomass in aqueous medium to obtain a supernatant;
[b] adding 4 volumes of ethanol to the supernatant of step [a] to precipitate the polysaccharides;
[C] dissolving the precipitated polysaccharide obtained from step [bj in water under stirring followed by filtration to obtain a filterate and a residue;
[d] suspending the residue obtained from step [c] in water to obtain water extractable hydro-suspension polysaccharide (Bio-RSIF);
[e] simultaneously, treating the filterate of step [c] with known deproteiπizatiαn agents to precipitate proteins and obtain a deproteinized supernatant;
[f] subjecting the supernatant obtained from step [e] to ethanot precipitation to obtain a precipitate;
[g] dissolving the precipitate obtained from step [f] in water to get water extractable easily water soluble polysaccharide fraction (Bio-RS1D).
16. A process as claimed in claim 15, wherein extraction may be carried out at any temperature upto boiling point of the extraction medium.
17. A process as claimed in claim 15, wherein the ethanol precipitated carbohydrates may be redissolved in normal or alkaline water and deproteinized.
18. A process as claimed in claim 15, wherein deproteinization may be carried out by precipitation with TCA, sodium acetate or by other routine way of selective precipitation of proteins.
19. A process as claimed in claim 15, wherein the deproteiπized supernatant may be subjected directly to ethaπol precipitation for sedimenting carbohydrate or after its desalting by dialysis or otherwise.
20. A process as claimed in claim 15, wherein the deproteinized polysaccharide preparation may be partially or completely purified through ϊon-exchange chromatography and/or size exclusion chromatography.
21. A process as claimed in claim 15, wherein the yield of bioactive polysaccharide fractions is 8% w/w for 'water extractable easily water soluble polysaccharides' (BiO-RSiD) and 15% w/w.for 'water extractable . hydro-suspension polysaccharides' (Bio-RS1 F).
22. A pharmaceutical composition useful as an immunomodulating agent, process for the preparation and use thereof substantially as herein described with reference to the foregoing examples.
27
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07734177A EP2010197A2 (en) | 2006-04-04 | 2007-04-03 | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof |
| CN2007800122740A CN101415432B (en) | 2006-04-04 | 2007-04-03 | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN954/DEL/2006 | 2006-04-04 | ||
| IN954DE2006 | 2006-04-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2007113646A2 WO2007113646A2 (en) | 2007-10-11 |
| WO2007113646A3 WO2007113646A3 (en) | 2008-07-03 |
| WO2007113646B1 true WO2007113646B1 (en) | 2008-09-12 |
Family
ID=38515779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2007/000856 WO2007113646A2 (en) | 2006-04-04 | 2007-04-03 | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2010197A2 (en) |
| CN (1) | CN101415432B (en) |
| WO (1) | WO2007113646A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CH00020A (en) * | 2014-01-03 | 2015-07-10 | Bathoju Gayathri | |
| RU2641599C1 (en) * | 2017-01-27 | 2018-01-18 | федеральное государственное автономное образовательное учреждение высшего образования "Северо-Кавказский федеральный университет" | Method for obtaining of spider plant herbal extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116948D0 (en) * | 2001-07-11 | 2001-09-05 | Sahajanand Biotech Private Ltd | Herbal formulation |
-
2007
- 2007-04-03 WO PCT/IB2007/000856 patent/WO2007113646A2/en active Search and Examination
- 2007-04-03 EP EP07734177A patent/EP2010197A2/en not_active Withdrawn
- 2007-04-03 CN CN2007800122740A patent/CN101415432B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2010197A2 (en) | 2009-01-07 |
| CN101415432B (en) | 2012-12-26 |
| CN101415432A (en) | 2009-04-22 |
| WO2007113646A3 (en) | 2008-07-03 |
| WO2007113646A2 (en) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi | Bioactivities, isolation and purification methods of polysaccharides from natural products: A review | |
| Tian et al. | Structural characterization and antioxidant activity of a low-molecular polysaccharide from Dendrobium huoshanense | |
| DK2701714T3 (en) | PROCEDURE FOR ISOLATING POLYSACCHARIDES | |
| US20090170801A1 (en) | Methods of treatment of cardiovascular and cerebrovascular diseases with fucoidan | |
| EP3287471A1 (en) | Polysaccharide suitable to modulate immune response | |
| US20090170810A1 (en) | Methods of treatment of cardiovascular and cerebrovascular diseases with low molecular weight fucoidan | |
| Nie et al. | Bioactive polysaccharides | |
| Lu et al. | Preparation of the Auricularia auricular polysaccharides simulated hydrolysates and their hypoglycaemic effect | |
| Gao et al. | The antitumor and immunostimulating activities of water soluble polysaccharides from Radix Aconiti, Radix Aconiti Lateralis and Radix Aconiti Kusnezoffii | |
| US20220304355A1 (en) | Identification and selection of a plant starting material of a plant chondroitin sulfate and hyaluronic acid, and transformation of such plant starting material to obtain ingredients for use in foods, supplements, medical devices or drugs | |
| WO2001064756A1 (en) | Salmon-origin chondroitin sulfate | |
| HU230385B1 (en) | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, their preparation and use and pharmaceutical compositions containing such derivatives | |
| Du et al. | Structure characterization of two novel polysaccharides isolated from the spikes of Prunella vulgaris and their anticomplement activities | |
| JP2015517602A (en) | Low molecular weight biotechnological chondroitin 6-sulfate for the prevention of osteoarthritis | |
| da Silva-Leite et al. | Polysaccharide rich fractions from barks of Ximenia americana inhibit peripheral inflammatory nociception in mice Antinociceptive effect of Ximenia americana polysaccharide rich fractions | |
| Mzoughi et al. | Pectic polysaccharides from edible halophytes: Insight on extraction processes, structural characterizations and immunomodulatory potentials | |
| Zeng et al. | Recent research advances in polysaccharides from Undaria pinnatifida: Isolation, structures, bioactivities, and applications | |
| CN110776578B (en) | Low-molecular sea cucumber glycosaminoglycan and application thereof | |
| Pangestuti et al. | Green seaweeds-derived polysaccharides ulvan: Occurrence, medicinal value and potential applications | |
| WO2008122214A1 (en) | The use of low molecular weight fucoidan in preparing of medicine for treating kidney diseases | |
| JPH0683652B2 (en) | Lipid metabolism-improved product and method for producing the same | |
| JPH0539305A (en) | Immuno suppressive polysaccharide extracted from astragalus membranaceous and pharma- ceutical composition containing same | |
| WO2007113646B1 (en) | A pharmaceutical composition useful as an immunomodulating agent and a process for the preparation thereof | |
| KR101949889B1 (en) | Method for preparing anticancer or immunactive polysaccharide from residues of immature citrus extract or immature citrus peel | |
| US20230203208A1 (en) | Process for extracting a hyaluronic acid from a fungus, a hyaluronic acid of plant origin and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 200780012274.0 Country of ref document: CN |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007734177 Country of ref document: EP |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07734177 Country of ref document: EP Kind code of ref document: A2 |